Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nityam Rathi

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Urologic Oncology|August 23, 2025
Renal surgery following HIF-2α antagonist therapy: Surgical indications, outcomes and growth kineticsDaniel Nethala, Braden Millan, Jason Hyman, et al.
Urologic Oncology|December 23, 2023
Functional recovery after partial nephrectomy in a solitary kidneyWorapat Attawettayanon, Yosuke Yasuda, Jj H Zhang, et al.
European Urology Open Science|August 7, 2023
Selective Use of Neoadjuvant Targeted Therapy Is Associated with Greater Achievement of Partial Nephrectomy for High-complexity Renal Masses in a Solitary KidneyWorapat Attawettayanon, Yosuke Yasuda, Jj H Zhang, et al.
Urology|February 6, 2025
A Fully Automated Artificial Intelligence-Based Approach to Predict Renal Function After Radical or Partial NephrectomyNour Abdallah, Nityam Rathi, Nicholas Heller, et al.
The Oncologist|November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate CancerLaura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
European Urology Oncology|December 14, 2022
Comprehensive Management of Renal Masses in Solitary KidneysYosuke Yasuda, Jj H Zhang, Worapat Attawettayanon, et al.
Cancer Medicine|January 19, 2021
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Shaan Dudani, J Connor Wells, et al.
European Urology Oncology|February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumFrede Donskov, Wanling Xie, Anders Overby, et al.
Eclinicalmedicine|June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective studyCassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.
JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Urologic Oncology|August 23, 2025
Renal surgery following HIF-2α antagonist therapy: Surgical indications, outcomes and growth kineticsDaniel Nethala, Braden Millan, Jason Hyman, et al.
Urologic Oncology|December 23, 2023
Functional recovery after partial nephrectomy in a solitary kidneyWorapat Attawettayanon, Yosuke Yasuda, Jj H Zhang, et al.
European Urology Open Science|August 7, 2023
Selective Use of Neoadjuvant Targeted Therapy Is Associated with Greater Achievement of Partial Nephrectomy for High-complexity Renal Masses in a Solitary KidneyWorapat Attawettayanon, Yosuke Yasuda, Jj H Zhang, et al.
Urology|February 6, 2025
A Fully Automated Artificial Intelligence-Based Approach to Predict Renal Function After Radical or Partial NephrectomyNour Abdallah, Nityam Rathi, Nicholas Heller, et al.
The Oncologist|November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate CancerLaura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
European Urology Oncology|December 14, 2022
Comprehensive Management of Renal Masses in Solitary KidneysYosuke Yasuda, Jj H Zhang, Worapat Attawettayanon, et al.
Cancer Medicine|January 19, 2021
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Shaan Dudani, J Connor Wells, et al.
European Urology Oncology|February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumFrede Donskov, Wanling Xie, Anders Overby, et al.
Eclinicalmedicine|June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective studyCassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.
JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
Pageof 8